Adobe Sign is 21 CFR Part 11 compliant only in one specific configuration: Adobe Acrobat Sign Enterprise with the Bio-Pharma settings turned on. Lower subscription tiers do not include the audit trail, authentication, and signature-meaning controls the FDA requires. And even at the Enterprise tier, the software itself is only part of the picture. The FDA holds your organization responsible for validating the system, writing standard operating procedures, training staff, and certifying to the agency that your electronic signatures are the legally binding equivalent of handwritten ones before you start using them in regulated workflows.
Which Adobe Sign Tier Actually Qualifies
Adobe Acrobat Sign sells at multiple subscription levels, but the Bio-Pharma configuration needed for Part 11 is available only in the Enterprise tier.1Adobe Help Center. Configure Bio-Pharma Settings Standard and lower plans handle basic electronic signatures well enough for ordinary business agreements, but they lack the tamper-evident audit trails, enforced identity authentication, and signature-meaning fields the regulation demands. If your team is currently running FDA-regulated workflows through a non-Enterprise version of Adobe Sign, those records probably do not meet federal requirements.
The Enterprise platform builds the Part 11 technical controls into a configuration layer that administrators enable during setup: audit trails, configurable authentication triggers, authority checks that restrict system functions to authorized users, and digital certificate options that cryptographically bind signers to their records. These are not add-ons or third-party integrations.
What the Bio-Pharma Settings Turn On
Administrators reach the Bio-Pharma configuration through the Account Settings menu on the Adobe Acrobat Sign Enterprise dashboard, inside the Electronic Signatures section.1Adobe Help Center. Configure Bio-Pharma Settings Enabling the settings activates several controls that map directly to Part 11 sections.
Reason for Signing
Part 11 requires every signed record to display the signer’s printed name, the date and time of signing, and the meaning of the signature, such as review, approval, responsibility, or authorship.2eCFR. 21 CFR 11.50 – Signature Manifestations Bio-Pharma’s “reason for signing” field forces signers to pick a meaning during the signing ceremony. The name and timestamp are captured automatically and embedded in the audit trail alongside the signature.
Identity Authentication Triggers
For electronic signatures that are not biometrics-based, Part 11 requires at least two distinct identification components, such as a user ID and password.3eCFR. 21 CFR 11.200 – Electronic Signature Components and Controls Bio-Pharma lets you require authentication at specific points in the signing flow: when the recipient opens the agreement, when they apply a signature, and when they complete it. That closes the gap where one user stays logged in and lets someone else sign under their credentials.
If your organization already runs SAML-based single sign-on, you can point Adobe Sign at your existing identity provider. Internal recipients then authenticate against your own SSO, including any multi-factor requirements you have in place, when the “Acrobat Sign authentication” method is triggered, and those internal users do not need a separate Acrobat Sign license.4Adobe Help Center. Enforce Identity Authentication
Audit Trails and Authority Checks
Part 11 requires secure, computer-generated, time-stamped audit trails that independently record every action creating, modifying, or deleting an electronic record, and changes must not obscure earlier entries.5eCFR. 21 CFR 11.10 – Controls for Closed Systems Adobe Acrobat Sign Enterprise generates these automatically, logging date, time, and IP address for every viewing, signing, and modification event, and stores the logs in read-only form. The audit trail must be retained at least as long as the underlying record and made available for FDA review.
The same section requires authority checks so that only authorized individuals can use the system, sign records, or access particular functions. Administrators configure this through roles and permissions inside the platform.
Signature-to-Record Linking
Electronic signatures must be linked to their records so they cannot be cut, copied, or transferred to falsify a different record.6eCFR. 21 CFR 11.70 – Signature/Record Linking When Adobe Sign applies a certificate-based digital signature, the cryptographic seal binds the signature to the document’s specific content. Any post-signing modification causes the signature to display as invalid, which flags tampering immediately during review.
Certificate-based digital signatures backed by the Adobe Approved Trust List are not strictly required by Part 11 for closed systems, but many regulated organizations choose them because they make document integrity easy to demonstrate during an FDA inspection.
What Adobe Cannot Do for You
Buying the right subscription and flipping on the Bio-Pharma toggles does not make your organization compliant. The FDA places the burden on you to show that the system is validated for its intended use and used under appropriate procedures and training.7U.S. Food and Drug Administration. Computer Software Assurance for Production and Quality Management System Software
Validate the System
Part 11 requires validation of systems to ensure accuracy, reliability, consistent intended performance, and the ability to detect invalid or altered records.5eCFR. 21 CFR 11.10 – Controls for Closed Systems Most organizations run validation as a three-phase protocol:
- Installation Qualification documents that the software is installed and configured correctly, including confirmation that Bio-Pharma settings are enabled.
- Operational Qualification tests that the system performs across its full operating range: audit trails capture the right data, authentication triggers fire correctly, user roles restrict access as configured, and error handling behaves as intended.
- Performance Qualification confirms the system produces consistent, specification-meeting results under real-world use over time.
Write Procedures and Train Staff
You need written standard operating procedures covering how the software is used, how data is protected, and how employees are trained. Part 11 specifically requires that everyone who develops, maintains, or uses the electronic records system has the education, training, and experience to perform assigned tasks.8eCFR. 21 CFR Part 11 – Electronic Records; Electronic Signatures Keep training records for everyone who touches the system. Written policies also have to hold individuals accountable for actions taken under their electronic signatures, which the rule treats as a deterrent to falsification.
Certify Electronic Signatures to the FDA
Before your organization starts using electronic signatures, or at the time it first does, it must certify to the FDA that those signatures are intended to be the legally binding equivalent of traditional handwritten signatures.9eCFR. 21 CFR 11.100 – General Requirements The certification itself is signed with a handwritten signature and submitted to the agency in electronic or paper form. The FDA may also request additional certification or testimony that a specific electronic signature is the legally binding equivalent of the signer’s handwritten one. Skip this step and your electronic signatures may not be recognized as valid regardless of how tightly the software is configured. Some organizations refer to the filing as a Letter of Non-Repudiation Agreement.
Open Systems Need More Than the Defaults
Part 11 treats closed systems and open systems differently. A closed system is one where access is controlled by the people responsible for the content of the records, such as your company’s internal network. An open system is one where access is not controlled by those people, such as records moving over the public internet.
Open systems must meet all the closed-system controls plus additional measures like document encryption and appropriate digital signature standards to protect authenticity, integrity, and confidentiality during transmission.10eCFR. 21 CFR 11.30 – Controls for Open Systems If you send regulated documents to outside parties through Adobe Sign over the internet, those extra protections apply. Certificate-based digital signatures and encrypted transmission carry more weight in this scenario.
Long Retention Periods and Expiring Certificates
Part 11 requires records to be protected so they can be accurately and readily retrieved through the entire retention period, with accurate and complete copies available in both human-readable and electronic form for FDA inspection.5eCFR. 21 CFR 11.10 – Controls for Closed Systems In pharmaceuticals and medical devices, retention can run for decades.
Digital certificates used to sign documents eventually expire, which creates a problem for records that outlive them. Long-term validation embeds the certificate verification information into the document at the time of signing, so a reviewer years later can still confirm that the signature and certificates were valid when executed. Confirm that your Adobe Sign configuration turns on LTV for signed documents, and consider pairing signed records with the PDF/A archival format for long-term accessibility.
What Happens If You Get It Wrong
The FDA has stated it will continue to enforce Part 11 requirements for system access controls and electronic signatures, and that it can take regulatory action for noncompliance with the underlying rules requiring records to be maintained or submitted.11U.S. Food and Drug Administration. Part 11, Electronic Records; Electronic Signatures – Scope and Application
Enforcement can include warning letters, rejection of data submissions, import alerts blocking products from entering the U.S. market, seizure of products already in distribution, injunctions halting manufacturing until violations are corrected, and consent decrees imposing court-supervised compliance obligations. Severity depends on the nature of the violation and how the organization responds. For companies running clinical trials or pursuing drug approvals, noncompliant electronic records can delay or derail approval itself, which usually costs more than any fine.